Table 6.
Indications for the orally administered anticoagulants warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban.
| Indication | Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|---|---|---|---|---|---|
| Arterial thrombosis | |||||
| Reduced risk of stroke and systemic embolism in patients with NVAF | yes | yes | yes | yes | yes |
| Prophylaxis and treatment of embolic complications associated with atrial fibrillation or cardiac valve replacement | yes | / | / | / | / |
| Reduced risk of death, recurrent myocardial infarction, and stroke or systemic embolism after myocardial infarction | yes | / | / | / | / |
| Venous thrombosis | |||||
| Prophylaxis of DVT and PE in patients who have undergone hip replacement surgery | yes | yes | yes | yes | / |
| Treatment of DVT and PE | / | yes | yes | yes | yes |
| Reduced risk of recurrent DVT and/or PE in patients at continued risk for recurrent of VTE | yes | yes | yes | yes | yes |
| Reduced risk of recurrent DVT and/or PE in patients at continued risk for recurrent of VTE in cancer patients | / | / | yes | yes | yes |